dasatinib

L-serine supplementation or dasatinib/quercetin administration to eliminate senescent cells alleviates both CS-induced neurobehaviors and peripheral hyperglycemia. Together, these findings reveal that HK2 in amygdaloid astrocytes mediates CS-induced neurobehaviors and hyperglycemia.

This case highlights a rare cytogenetic abnormality in CML characterized by acquired pericentric inversion of the derivative chromosome 9 associated with BCR and ABL1 codeletion. Such complex rearrangements likely reflect clonal evolution and may be associated with suboptimal response to first line imatinib therapy. Accurate discrimination between constitutional and acquired inv(9), together with detailed assessment of derivative chromosome 9 integrity, is essential for prognostic stratification. Comprehensive cytogenetic and molecular analyses remain critical for identifying uncommon secondary abnormalities that may influence therapeutic response and clinical outcome in CML.

Dasatinib de-escalation after 100 mg standard dose achieved superior early response, fewer discontinuations, and sustained outcomes versus upfront low-dose therapy. This first Indian study supports de-escalation as an effective, real-world dose-optimization strategy.

P1, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

Subsequently, he was started on systemic therapy with dasatinib in combination with the HyperCVAD chemotherapy regimen...Ocular features such as diplopia in the setting of chronic unexplained headache should prompt careful fundus examination, as it may reveal critical clues to underlying intracranial pathology. Early neuroimaging, timely biopsy, and rapid initiation of systemic therapy remain critical for optimizing outcomes.

DPP4 expression was assessed by qPCR in 22Rv1 and C4-2 cells treated with dasatinib or midostaurin at IC50 concentrations. On the contrary, DPP4 expression in both 22Rv1 and C4-2 was reduced after treatment with midostarin (p < 0.05). Our study establishes DPP4 as a multifaceted pan-cancer biomarker with prognostic significance and immunotherapeutic implications, particularly in prostate cancer.

P2, N=222, Recruiting, National Cancer Institute (NCI) | Phase classification: P3 --> P2

P3, N=348, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting

P2, N=25, Suspended, University of Chicago | Recruiting --> Suspended

This study uncovers a previously unrecognized synergistic anti-tumor effect between LRPPRC inhibition and Dasatinib, mediated by complementary suppression of nuclear- and mitochondrial genome-encoded OXPHOS pathways. These findings provide a strong mechanistic and translational rationale for combination therapies targeting LRPPRC-high tumors.

Vorinostat exhibited the highest binding affinity to TPX2 (-29.32 kcal/mol) and BUB1B (-23.71 kcal/mol), followed by BRD-K90370028 (-18.40 kcal/mol on BUB1B), NSC19630 and Dasatinib (with consistent dual-target binding), CD-437, and four additional prioritised compounds that exhibited favourable interactions. In conclusion, this coherent transcriptomics-to-therapeutics workflow establishes TPX2 and BUB1B as strong prognostic biomarkers in BC, with promising repurposed drugs targeting these mitotic regulators.

It informed personalized treatment strategies, revealing differential sensitivity to therapeutic agents including dasatinib and UMI-77...Integrated multi-omics analyses reveal a strong association between disulfidptosis and an immunosuppressive tumor microenvironment, positioning it as a candidate metabolic vulnerability that warrants further functional investigation. These findings offer correlative insights into the involvement of disulfidptosis in immune regulation and suggest that further exploration of this pathway may inform future immunotherapeutic strategies.